Pfizer Terminates Domagrozumab (PF-06252616) Clinical Studies for the Treatment of Duchenne
We are deeply disappointed to learn that Pfizer is terminating two ongoing clinical studies evaluating domagrozumab (PF-06252616) for the treatment of Duchenne: a Phase 2 safety and efficacy study (B5161002) and an open-label extension study…Learn More